Preclinical Evaluation of Fluorine-18-Labeled Androgen Receptor Ligands in Baboons

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 1009-1015

  Bonasera, Thomas A ^b   O'Neil, James P ^b   Xu, Ming ^b   Dobkin, Jeffrey A ^b   Cutler, P Duffy ^b   Lich, Lennis L ^b   Choe, Yearn Seong ^b   Katzenellenbogen, John A ^b   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

5 dihydrotestosterone; Androgen receptor; Mibolerone; Positron emission tomography; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; MIBOLERONE; NANDROLONE; TESTOSTERONE DERIVATIVE;

ANIMAL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SCREENING; MALE; METABOLISM; PAPIO; PROSTATE; PROSTATE TUMOR; SCINTISCANNING;

ANIMALS; DIHYDROTESTOSTERONE; DRUG EVALUATION, PRECLINICAL; FLUORINE RADIOISOTOPES; MALE; NANDROLONE; PAPIO; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE CONGENERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030160448     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Wango PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995;45:8-30.
2. Blankenstein MA, Bolt-de Vries J, van Aubel OG, van Steenbrugge GJ. Hormone receptors in human prostate cancer. Scan J Urol Nephrol 1988;107:39-45.
3. Barrack ER, Tindall DJ. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. In: Coffey DS, ed. Current concepts and approaches to the study of prostatic cancer. New York, NY: Alan R. Liss; 1987:155-187.
4. Concolino G, Maroechi A, Margiotta G, et al. Steroid receptors and hormone responsiveness of human prostatic carcinoma. Prostate 1982;3:475-482.
5. Diamond DA, Barrack ER. The relationship of androgen receptor level to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. Urology 1984;132: 821-827.
6. Ekman P, Snochowski M, Dahlberg E, Gustafsson JÅ. Steroid receptors in metastatic carcinoma of the human prostate. Eur J Can 1979;15:257-262.
7. Ekman P, Snochowski M, Zetterberg A, Högberg B, Gustafsson JÅ. Steroid receptor content in human prostatic carcinoma and response to endocrine therapy. Cancer 1979;44:1173-1181.
8. Ekman P, Dahlberg E, Gustafsson JA, Högberg B, Pousette A, Snochowski M. Present and future clinical value of steroid receptor assays in human prostatic carcinoma. In: Lacobelli S, ed. Hormones and cancer. New York, NY: Raven Press; 1980;361-370.
9. Katzenellenbogen JA. The development of gamma-emitting hormone analogs as imaging agents for receptor-positive tumors. In: Murphy GP, Sandberg AA, eds. The prostatic cell: structure and function part B New York, NY: Alan R. Liss; 1981:313-327.
10. Pertschuk LP, Rosenthall HE, Macchia RJ, et al. Correlation of histochemical and biochemical analysis of androgen binding in prostatic cancer: relation to therapeutic response. Cancer 1982;49:984-993.
11. Mobbs BG, Johnson IE. Basal and estrogen-stimulated hormone receptor profiles in tour R3327 rat prostatic carcinoma sublines in relation to histopathology and androgen sensitivity. Cancer Res 1988;48:3077-3083.
12. Müntzing J, Kirdani RY, Murphy GP, Sandberg AA. A rat prostatic adenocarcinoma as a model for the human disease. Invest Urol 1979;17:37-41.
13. Trapma J, Stalpers CK, van der Korpul JAGM, Kuiper GGJM, Brinkmann AO. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate cell lines. J Steroid Biochem Mol Biol 1990;37:837-842.
14. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer: heterogeneity as a predictor of response to hormonal therapy. Cancer 1993;71:2574-2580.
15. Neri R. Pharmacology and pharmacokinetics of flutamide. Urology 1989;34(suppl): 19-21.
16. Mobbs BG, Johnson IE, Connolly JG. The effect of therapy on the concentration and occupancy of androgen receptors in the human prostatic cytosol. Prostate 1980;1:37- 51.
17. Mobbs BG, Johnson JF, Connolly JG, Thompson J. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J Steroid Biochem 1983;19:1279-1289.
18. Mobbs BG, Johnson IE. Increased androgen binding capacity in experimental prostatic carcinomas treated with estrogen. Prog Cancer Res Therapy 1984;31:467-476.
19. Karr JP, Wajsman Z, Madajewicz S, Kurdani RY, Murphy GP, Sandberg AA. Steroid hormone receptors in the prostate. J Urol 1979;122:170-175.
20. Motta M, In: Denis L, ed. The endocrinological basis for hormonal therapy of prostate tumors. The medical management of prostate cancer II. Berlin, Germany: Springer- Verlag; 1991;27-44.
21. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplication of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995;9:401- 406.
22. 18F]fluoro-19-nor-5α- dihydrotestosterone: preparation via halofluorination-reduction, receptor binding and tissue distribution. J Med Chem 1995;38:816-825.
23. 18F]Fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 1991;32:81-88.
24. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992;33:724- 734.
25. Reiffers S, Vaalburg W, Weigman T, Wynberg H, Woldring MG. Carbon-11-labeled methyllithium as methyl donating agent: the addition to 17-keto steroids. Int J Appl Radiat Isot 1980;31:535-539.
26. 11C-17α-methyltestosterone. Int J Appl Radiat Isot 1981;32:811-815.
27. 77Br-labeled 5α-dihydrotestosterone for scanning of the prostate. Eur J Nucl Med 1977;2:155-157.
28. Eakins MN, Waters SL. Synthesis of bromine-77-labeled 5α-dihydrotestosterone and a comparison of its distribution in rats with bromine-77-bromide. Int J Appl Radiat Isot 1979;30:701-704.
29. Hample R, Horakova J, Bickova M, Dvorak P, Starka L. Iodo derivatives of testosterone as potential biological markers. J Steroid Biochem 1980;13:1035-1038.
30. 125l]-iodo-5α-dihydrotestosterone and evaluation of its affinity for the androgen receptor. J Steroid Biochem 1982;16:621-628.
31. Hoyte RM, MacLusky NJ. Hochberg RB. The synthesis and testing of E-17α-(2- iodovinyl)-5α-dihydrotestosterone and Z-17α-(2-iodovinyl)-5α-dihydrotestosterone as gamma-emitting ligands for the androgen receptor. J Steroid Biochem 1990;36:125- 132.
32. Hoyte RM, Borderon K, Bryson K, Allen R, Hochberg RB, Brown TJ. Synthesis and evaluation of 7α-iodo-5α-dihydrotestosterone as a potential radioligand for the androgen receptor. J Med Chem 1994;37:1224-1230.
33. Tarle M, Padovan R, Spaventi S. The uptake of radioiodinated 5-alpha-dihydrotestosterone by the prostate of intact and castrated rats. Eur J Nucl Med 1981;6:79-83.
34. Skinner RWS, Pozerac RV, Counsell RE, Hsu CF, Weinhold PA. Androgen receptor binding properties and tissue distribution of 2-selena-A-nor-5α-androstan-17β-ol in the rat. Steroids 1977;30:15-23.
35. Carlson KE, Katzenellenbogen JA. A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat. J Steroid Biochem 1990;36:549-561.
36. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992;20:281-295.
37. Kumar VL, Wadhwa SN, Kumar V, Farooq A. Androgen, estrogen and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122-128.
38. Young JDJ, Sidh SM, Bashirelahi N. The role of estrogen, androgen and progestogen receptors in the management of carcinoma of the prostate. Trans Amer Assoc Gen-Urin Surg 1979;71:23-25.
39. Gustafsson JÅ, Ekman P, Pousette A, Snochowski M, Hogberg B. Demonstration of a progestin receptor in human benign prostatic hyperplasia and prostatic carcinoma. Invest Urol 1978;15:361-366.
40. Hobbs CJ, Jones RE, Plymate SR. The effects of sex hormone binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid. J Steroid Biochem Mol Biol 1992;42:629-635.
41. Reventos J, Sullivan PM, Joseph DR, Gordon JW. Tissue-specific expression of the rat androgen-binding protein/sex hormone-binding globulin gene in transgenic mice. Mol Cellular Endacrin 1993;96:69-73.
42. Brandes SJ, Katzenellenbogen JA. Fluorinaled androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol Pharmacol 1987;32:391-403.
43. Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 1992;35:2113-2129.
44. Tait JF, Tait SAS. The effect of plasma protein binding on the metabolism of steroid hormones. J Endocrinol 1991;131:339-357.
45. Noé G, Cheng YC, Dabiké M, Croxatto HB. Tissue uptake of human sex hormone-binding globulin and its influence on ligand kinetics in the adult female rat. Biol Reprod 1992;47;970-976.
46. Krupenko SA, Krupenko NI, Danzo BJ. Interaction of sex hormone-binding globulin with plasma membranes from the rat epididymis and other tissues. J Steroid Biochem Mol Biol 1994;51:115-124.
47. Porto CS, Abreu LC, Gunsalus GL, Bardin CW. Binding of sex hormone-binding globulin (SHBG) to testicular membranes and solubilized receptors. Mol Cellular Endocrin 1992;89:33-38.
48. Shiina H, Ishibe T, Usui T. Interaction of testosterone-oestradiol binding globulin [TcBG) and albumin with human prostatic carcinoma in vitro. Int J Urol Nephrol 1993;25:577-582.
49. Müntzing J. Myhrberg H, Saroff J, Sandberg AA, Murphy GP. Histochemical and ultrastructural study of proslalic tissue from baboons treated with antiprostatic drugs. Invest Urol 1976;14: 162-167.
50. Kaack B, Lewis RW, Resnick MI, Roberts JA. Biochemistry of the nonhuman primate prostate and seminal vesicles. I. Some chemical parameters. Arch Androl 1983;11: 123-129.
51. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled cstrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984;25:1212-1221.
52. 77Br]-11β-methoxyestradiol, two estrogen receptor-binding radiopharmaceuticals. Int J Appl Radiat Isot 1982;33:545-551.
53. Welch MJ, Kilbourn MR. A remote system for the routine production of oxygen-15 radiopharmaceuticals. J Label Cmpds Radiopharm 1985;22:1193-1200.
54. Yamamoto M, Ficke DC, Ter-Pogossian MM. Performance study of PETT VI, a positron computed tomograph with 288 cesium fluoride detectors. IEEE Trans Nucl Sci 1982;NS-29:529-533.
55. Tcr-Pogossian MM, Ficke DC, Hood JT Sr, Yamamoto M, Mullani NA. PETT VI: a positron emission tomograph utilizing cesium fluoride scintillation detectors. J Comput Assist Tomogr 1982;6:125-133.
56. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labelcd water and positron emission tomography. J Am Coll Cardiol 1989;14:639-652.
57. Sorenson JA, Phelps ME. Physics in nuclear medicine, 2nd ed. Philadelphia, PA: W.B. Saunders Corp.; 1987, 406-408.
58. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 1-methionine. J Nucl Med 1985;26:37-42.
59. Swindler DR, Wood CD. An atlas of primate gross anatomy. Seattle, WA: University of Washington Press; 1973:370.
60. 3H]-5α-dihydrotestosterone binding proteins in the accessory sexual glands of the male Syrian hamster. J Steroid Biochem 1978;9:317-324.
61. Takane KK, Husmann DA, McPhaul MJ, Wilson JD. Androgen receptor levels in the rat penis are controlled differently in distinctive cell types. J. Urol 1991;128:2234-2238.
62. Nonomura K, Sakakibara N, Demura T, Mori T, Koyanagi T. Androgen binding activity in the spongy tissue of mammalian penis. J Urol 1990;144:152-155.
63. Pomper MG, VanBrocklin HF, Thieme AM, et al. 11β-Methoxy-, 11β-cthyl- and 17α-cthynyl-substituted 16α-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 1990;33:3143-3155.
64. 18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sci 1993;53:811-819.
65. Kiesewetter DO, Katzenellenbogen JA, Kilbourn MR, Welch MJ. Synthesis of 16-fluoroestrogens by unusually facile fluoride ion displacement reactions: prospects for the preparation of fluorine- 18-labeled estrogens. J Org Chem 1984;49:4900-4905.
66. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-1774.
67. 18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-1531.
68. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-48.
69. Wagner RK. Extracellular and intracellular steroid binding proteins. Properties, discrimination, assay and clinical applications, Acta Endocrinol 1978;88:1-73.
70. Bonasera TA, O'Neil JP, Choc YS, et al. Imaging the prostate in baboons with fluorine-18-labeled androgen receptor ligands. J Nucl Med 1994;35:53P.